Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer
Adjuvant Intraperitoneal Chemotherapy Guided by the Detection of Cancer Cell DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer: an Open-label, Phase 2 Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Introduction:
Peritoneal metastasis is the most common pattern of gastric cancer recurrence and leads to rapid death. In a previous study, our team established a personalized method which could detect minimal cancer cell DNA in peritoneal lavage fluid with high sensitivity and specificity. We intend to perform a clinical trial to explore the efficacy of intraperitoneal chemotherapy on reducing the incidence of peritoneal metastases in patients with high risk defined by our personalized mutation detection method.
Methods and analysis:
This is a single-arm and single-center clinical trial. Sixty-eight patients with clinical T4 stage gastric cancers will be expected to be enrolled. During surgery, surgeons will wash upper abdominal cavity with 300-400 mL of normal saline before any manipulation of the tumor and collect about 200 mL peritoneal lavage fluid. Cancer cell DNA in peritoneal lavage fluid will be detected by next-generation sequencing using a personalized tumor-specific mutation profiling assay. Patients with positive peritoneal lavage fluid cancer cell DNA will receive adjuvant intraperitoneal chemotherapy in the second month since surgery, then followed by standard adjuvant systemic chemotherapy.
The primary endpoint is the incidence of peritoneal metastasis, and the secondary endpoints include peritoneal metastasis-free survival, disease-free survival (DFS), overall survival (OS), and the safety of intraperitoneal chemotherapy.
Ethics
This trial has been approved by the Ethics Committee of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Recruiting
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Criteria:
- Gastric adenocarcinoma confirmed by pathology (histology);
- 18-75 years old;
- Clinical T4 stage, no distant metastasis confirmed by CT and endoscopic ultrasonography (EUS), potentially curable by surgery;
- Eastern Cooperative Oncology Group Performance Score 0 or 1;
- Absolute neutrophil count at least 1.5×10^9/L; platelets count at least 80×10^9/L; hemoglobin at least 9 g/dL; serum creatinine or creatinine clearance no greater than 1.5 times upper normal limit (UNL); TSB no greater than 1.5 times ULN; AST (SGOT) and ALT (SGPT) no greater than 2.0 times ULN; albumin at least 3.0 mg/dL;
- Provide tumor tissue, blood, and peritoneal lavage fluid samples;
- Willing to accept long-term follow-up;
- Ability to understand and sign a written informed consent before the trial procedure.
Exclusion Criteria
- Currently participating in or receiving other clinical trial treatment;
- Contraindications to investigational chemotherapy regimen including allergies to any of the chemotherapy medications;
- Active infection requires systemic treatment;
- Patients with poor compliance;
- Patients who undergo non-curative surgery;
- History of other malignant neoplasm within 5 years, except for early-stage skin cancer;
- Pregnant or breast-feeding female;
- Patients who have received neoadjuvant therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intraperitoneal chemotherapy group
In this study, patients with positive peritoneal lavage fluid cancer cell DNA will be given intraperitoneal chemotherapy followed by adjuvant systemic chemotherapy.
|
5-Fu 1 g/m^2 on Days 1, 8, 15, and 22; Albumin-paclitaxel 80-100 mg/time on Days 1, 8, 15, and 22; Cisplatin 25 mg/m^2 on Days 4, 11, 18, and 25; Interleukin-2 2 million units/time on Days 4, 11, 18, and 25.
Oxaliplatin 85 mg/m^2 on Day 1; S-1 depends on Body Surface Area (BSA), 40 mg Bid, Days 1-10 (BSA < 1.25 m^2), 50 mg Bid, Days 1-10 (BSA 1.25-1.50
m^2), 60 mg Bid, Days 1-10 (BSA > 1.50 m^2).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The incidence of peritoneal metastasis
Time Frame: Two years after surgery.
|
The incidence of peritoneal metastasis.
|
Two years after surgery.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peritoneal metastasis-free survival
Time Frame: Two years after surgery.
|
The time from surgery to peritoneal metastasis.
|
Two years after surgery.
|
|
Disease-free survival
Time Frame: Three years after surgery.
|
The time from surgery to either recurrence or relapse of cancer, or death.
|
Three years after surgery.
|
|
Overall survival
Time Frame: Three years after surgery.
|
The time from surgery to death or the last follow-up date.
|
Three years after surgery.
|
|
The safety
Time Frame: Ninety days after surgery.
|
Adverse event and complications related to intraperitoneal chemotherapy.
Adverse event is defined by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0.
Complications will be recorded and graded according to the modified Clavien-Dindo classification.
|
Ninety days after surgery.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21/458-3129
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.